Can I get retatrutide from a compounding pharmacy right now?

No. The FDA states that retatrutide cannot be used in compounding under federal law, because it is not a component of any FDA-approved drug. The agency has taken action against sellers of unapproved retatrutide products. A compounded or 'research' vial is not a legal or verified version of Lilly's molecule.

Do people in the TRIUMPH trials pay for retatrutide?

No. Study drug in a sponsor-run clinical trial is supplied by the sponsor at no cost to participants. That is why trial supply tells you nothing about a future retail price. Enrollment is the only legal way to receive retatrutide in the United States today.

Will my Zepbound or Wegovy savings card work for retatrutide?

No. Manufacturer savings cards are tied to one specific product and its FDA-approved uses. Lilly has not announced any patient support program for retatrutide, and it cannot run one before approval. Any new program would be published on Lilly's own site after launch.

Does the $274 Medicare negotiated price for semaglutide apply to retatrutide?

No. CMS negotiates prices for high-expenditure, single-source drugs that have been on the market without generic or biosimilar competition. A newly approved medicine is not eligible for selection. The $274 figure applies to Ozempic, Rybelsus, and Wegovy starting January 1, 2027.

How fast would insurance start covering retatrutide after an FDA approval?

Coverage rarely starts on approval day. Pharmacy benefit managers review new drugs on their own schedule and usually add prior authorization criteria first. Employer plans often wait for the next plan year to change a formulary. Expect a gap between approval and reliable coverage.

What Will Retatrutide Cost And Will Insurance Cover It?

The short answer: Retatrutide has no price and no insurance coverage today. It is an investigational Eli Lilly molecule, and Lilly said in July 2026 that it plans to file with the FDA in the first quarter of 2027. No pharmacy can legally sell it and no health plan can cover it until the FDA approves it. The only honest guide is what approved obesity drugs cost right now: Lilly lists Zepbound self-pay at $299 to $699 a month, and Novo Nordisk lists Wegovy self-pay at $349 a month.

Is there a price for retatrutide yet?

No. Lilly's own July 23, 2026 release describes retatrutide as "an investigational molecule that cannot be legally sold or marketed for human use". An earlier Lilly release put it more plainly: the drug is legally available only to people enrolled in Lilly's clinical trials.

In that same July 2026 release, Lilly said it plans to submit retatrutide to the FDA in the first quarter of 2027. A submission is not an approval. The agency then has to review the file, and Lilly has more phase 3 data still to report. ClinicalTrials.gov lists 33 retatrutide studies, including a head-to-head trial against tirzepatide (NCT06662383) with a primary completion date of November 2026.

So any site quoting you a monthly price for retatrutide is not quoting Lilly's product. There is no list price, no copay tier, and no formulary placement to quote. For the approval timeline, see when retatrutide could be FDA approved.

What do today's obesity drugs cost?

These are the real anchors. All figures below come from the manufacturers' own pages, read on September 5, 2026. Drug prices change often, so check the source before you rely on a number.

Zepbound (tirzepatide), Lilly. Lilly's Zepbound coverage and savings page lists the regular self-pay price for a one-month supply of the single-patient-use KwikPen as $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg, and 15 mg.
Zepbound with commercial insurance. The same page says people whose commercial plan covers Zepbound may pay as little as $25 for a one-month fill through Lilly's savings program, with card savings capped per fill and per year.
Wegovy (semaglutide), Novo Nordisk. NovoCare Pharmacy lists self-pay Wegovy injection at $349 a month for the 0.25 mg through 2.4 mg doses, $399 a month for Wegovy HD 7.2 mg, and an introductory $199 a month for the first two fills through December 31, 2026.
Oral semaglutide. The same NovoCare page lists the tablet at $149 a month for 1.5 mg, $199 a month for 4 mg, and $299 a month for 9 mg and 25 mg.

Insured list prices are much higher than these cash prices. In its fact sheet on negotiated prices for 2027, CMS put the 2024 list price for Ozempic, Rybelsus, and Wegovy at $959 for a 30-day supply. CMS negotiated that down to $274 for Medicare, effective January 1, 2027, a 71% discount. For a wider view of this drug class, see glp1.md.

What will set retatrutide's launch price?

Four things will do most of the work, and none of them are settled.

Competition. Retatrutide would launch into a market where tirzepatide and semaglutide already sell direct to consumers at a few hundred dollars a month. That is a very different starting point from Wegovy's 2021 launch.
The cash-pay channel. Both makers now run their own pharmacies with published self-pay prices. A third entrant has an obvious template to copy.
How many indications it wins. Lilly says it has data to support submissions in obesity, knee osteoarthritis pain, and obstructive sleep apnea. A drug with several approved uses is easier to place on a formulary than a weight-only drug. Our page on the sleep apnea and knee osteoarthritis results covers that evidence.
Effect size. In TRIUMPH-1, people on 12 mg lost an average of 70.3 lbs (28.3%) at 80 weeks, and 85.0 lbs (30.3%) at 104 weeks in an extension. Stronger results give a manufacturer more pricing room, but they also raise the bar for what payers demand in return.

Will Medicare cover retatrutide?

Not under standard Part D rules as they stand. Medicare law excludes agents when used for weight loss, and that exclusion has been in place since Part D began. CMS proposed reinterpreting it in late 2024, then did not finalize that proposal in the April 2025 Medicare Advantage and Part D rule.

Instead, CMS built a workaround. Its BALANCE model covers a named list of GLP-1 medicines for weight management: Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen, and Foundayo. Medicaid coverage under BALANCE starts as early as May 2026. For Part D, CMS runs a separate Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027.

According to KFF's summary, the Bridge uses a negotiated net price of $245 per month and caps the patient copay at $50 a month. Lilly's Zepbound page shows the same $50 monthly figure for eligible Part D patients. KFF also notes that BALANCE was postponed indefinitely in Part D on April 21, 2026, after too few plans applied.

Two things follow for retatrutide. It is not on that named drug list, and it cannot be until it is approved. And a demonstration program with an end date is not the same as permanent Part D coverage.

What about employer plans and Medicaid?

Employer coverage of this class is growing but still far from universal. KFF's 2025 Employer Health Benefits Survey found that among firms offering benefits, 16% of those with 200 to 999 workers, 30% of those with 1,000 to 4,999 workers, and 43% of those with 5,000 or more workers covered GLP-1 agonists when used primarily for weight loss. Coverage at the largest firms rose from 28% in 2024 to 43% in 2025.

Cost pressure is the reason coverage is not higher. In the same survey, 66% of firms with 5,000 or more workers said covering GLP-1 agonists for weight loss had a significant impact on their prescription drug spending.

Expect the usual controls to apply to retatrutide if it is approved: prior authorization, a BMI threshold, documented lifestyle effort, and sometimes step therapy through a cheaper agent first. State Medicaid programs vary widely, and BALANCE gives states an optional route rather than a mandate.

One lever matters more than the rest. A non-weight indication changes the coverage conversation, because the weight-loss exclusion no longer applies. Zepbound's December 2024 approval for moderate-to-severe obstructive sleep apnea in adults with obesity is the clearest example so far.

What about cheap gray-market retatrutide?

Vials sold online for a fraction of a brand price are not a preview of retatrutide's real cost. The FDA's page on unapproved GLP-1 drugs used for weight loss, updated September 1, 2026, states that "retatrutide and cagrilintide cannot be used in compounding under federal law" and that they "are not components of FDA-approved drugs and have not been found safe and effective for any condition."

The agency also says it has acted against companies that illegally sold unapproved drugs containing retatrutide and similar peptides while labeling them "for research purposes" or "not for human consumption." Those products carry no verified identity, purity, or dose. We go through the specific risks in is gray-market retatrutide safe.

The bottom line

Retatrutide has no price because it is not a product yet. Lilly's stated plan is an FDA submission in the first quarter of 2027, and price and formulary decisions come after approval, not before. If you want a realistic budget number today, use the approved comparators: $299 to $699 a month for Zepbound self-pay, $349 a month for Wegovy self-pay, and much higher list prices behind insurance. Coverage will hinge less on the drug's weight-loss numbers than on which indications it wins and whether Medicare's exclusion of weight-loss agents ever changes.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Retatrutide is investigational and is not approved or available by prescription. Prices and coverage rules change frequently, so verify any figure with the manufacturer or your health plan, and talk with your clinician about treatment options.